Dermatofibrosarcoma protuberans

Jump to: navigation, search

WikiDoc Resources for Dermatofibrosarcoma protuberans


Most recent articles on Dermatofibrosarcoma protuberans

Most cited articles on Dermatofibrosarcoma protuberans

Review articles on Dermatofibrosarcoma protuberans

Articles on Dermatofibrosarcoma protuberans in N Eng J Med, Lancet, BMJ


Powerpoint slides on Dermatofibrosarcoma protuberans

Images of Dermatofibrosarcoma protuberans

Photos of Dermatofibrosarcoma protuberans

Podcasts & MP3s on Dermatofibrosarcoma protuberans

Videos on Dermatofibrosarcoma protuberans

Evidence Based Medicine

Cochrane Collaboration on Dermatofibrosarcoma protuberans

Bandolier on Dermatofibrosarcoma protuberans

TRIP on Dermatofibrosarcoma protuberans

Clinical Trials

Ongoing Trials on Dermatofibrosarcoma protuberans at Clinical

Trial results on Dermatofibrosarcoma protuberans

Clinical Trials on Dermatofibrosarcoma protuberans at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Dermatofibrosarcoma protuberans

NICE Guidance on Dermatofibrosarcoma protuberans


FDA on Dermatofibrosarcoma protuberans

CDC on Dermatofibrosarcoma protuberans


Books on Dermatofibrosarcoma protuberans


Dermatofibrosarcoma protuberans in the news

Be alerted to news on Dermatofibrosarcoma protuberans

News trends on Dermatofibrosarcoma protuberans


Blogs on Dermatofibrosarcoma protuberans


Definitions of Dermatofibrosarcoma protuberans

Patient Resources / Community

Patient resources on Dermatofibrosarcoma protuberans

Discussion groups on Dermatofibrosarcoma protuberans

Patient Handouts on Dermatofibrosarcoma protuberans

Directions to Hospitals Treating Dermatofibrosarcoma protuberans

Risk calculators and risk factors for Dermatofibrosarcoma protuberans

Healthcare Provider Resources

Symptoms of Dermatofibrosarcoma protuberans

Causes & Risk Factors for Dermatofibrosarcoma protuberans

Diagnostic studies for Dermatofibrosarcoma protuberans

Treatment of Dermatofibrosarcoma protuberans

Continuing Medical Education (CME)

CME Programs on Dermatofibrosarcoma protuberans


Dermatofibrosarcoma protuberans en Espanol

Dermatofibrosarcoma protuberans en Francais


Dermatofibrosarcoma protuberans in the Marketplace

Patents on Dermatofibrosarcoma protuberans

Experimental / Informatics

List of terms related to Dermatofibrosarcoma protuberans

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Kiran Singh, M.D. [2], Faizan Sheraz, M.D. [3]

Synonyms and Keywords: : Darier-Ferrand tumor, Darier-Hoffmann tumor, dermatofibrosarcoma, DFSP


Dermatofibrosarcoma protuberans (DFSP) is a rare neoplasm of the dermis layer of the skin, and is classified as a sarcoma. In many respects, the disease behaves as a benign tumor, but in 2-5% of cases it can metastasize, so it should be considered to have malignant potential.

Over 95% of DFSP tumors have the chromosomal translocation t(17;22). The translocation fuses the collagen gene (COL1A1) with the platelet-derived growth factor gene. The fibroblast, the cell of origin of this tumor, expresses the fusion gene in the belief that it is collagen. However the resulting fusion protein is processed into mature platelet-derived growth factor which is a potent growth factor. Fibroblasts contain the receptor for this growth factor. Thus the cell "thinks" it is producing a structural protein, but in fact produces a self-stimulatory growth signal. The cell divides rapidly and a tumor forms. In dermatofibrosarcoma protuberans, the tumor has a tendency to return after being removed. However, it does not often metastasize to other parts of the body.


Dermatofibrosarcoma protuberans is associated with a rearrangement (translocation) of genetic material between chromosomes 17 and 22. This translocation, written as t(17;22), fuses part of the COL1A1 gene from chromosome 17 with part of the PDGFB gene from chromosome 22. The translocation is found on one or more extra chromosomes that can be either the normal linear shape or circular. When circular, the extra chromosomes are known as supernumerary ring chromosomes. Ring chromosomes occur when a chromosome breaks in two places and the ends of the chromosome arms fuse together to form a circular structure. Other genes from chromosomes 17 and 22 can be found on the extra chromosomes, but the role these genes play in development of the condition is unclear. The translocation is acquired during a person's lifetime and the chromosomes containing the translocation are present only in the tumor cells. This type of genetic change is called a somatic mutation. In normal cells, the COL1A1 gene provides instructions for making part of a large molecule called type I collagen, which strengthens and supports many tissues in the body. The PDGFB gene provides instructions for making one version (isoform) of the platelet derived growth factor (PDGF) protein. By attaching to its receptor, the active PDGFB protein stimulates many cellular processes, including cell growth and division (proliferation) and maturation (differentiation). The abnormally fused COL1A1-PDGFB gene provides instructions for making an abnormal combined (fusion) protein that researchers believe ultimately functions like the PDGFB protein. The gene fusion leads to the production of an excessive amount of protein that functions like the PDGFB protein. In excess, this fusion protein stimulates cells to proliferate and differentiate abnormally, leading to the tumor formation seen in dermatofibrosarcoma protuberans. The COL1A1-PDGFB fusion gene is found in more than 90 percent of dermatofibrosarcoma protuberans cases. In the remaining cases, changes in other genes may be associated with this condition. These genes have not been identified[1].


There are several variants of dermatofibrosarcoma protuberans in which different cell types are involved in the tumor. Bednar tumors, often called pigmented dermatofibrosarcoma protuberans, contain dark-colored (pigmented) cells called melanin-containing dendritic cells. Myxoid dermatofibrosarcoma protuberans tumors contain an abnormal type of connective tissue known as myxoid stroma. Giant cell fibroblastoma, which is sometimes referred to as juvenile dermatofibrosarcoma protuberans because it typically affects children and adolescents, is characterized by giant cells in the tumor.

Epidemiology and Demographics

Dermatofibrosarcoma protuberans is estimated to occur in 1 in 100,000 to 1 in 1 million people per year.

Differential Diagnosis

Dermatofibrosarcoma protuberans must be differentiated Neurofibroma must be differentiated from:[2][3][4]

Differentiating neurofibroma from other diseases
Disease entity Etiology (Genetic or others) Histopathological findings Immunohistochemical staining Risk factors Common site of involvement Clinical manifestations Other associated features

Can be sporadic or as a part of Neurofibromatosis 1 and 2

Neurofibroma with degenerative atypia ("ancient change") has following microscopic features:

Positive for:

Negative for:

Schwannoma[16][17][18][19][20] Positive for:

Negative for:

Symptoms of schwannoma depend on the location of the tumor:

Palisaded encapsulated neuroma (PEN) /solitary circumscribed neuroma[21] Positive for:

Negative for:

90% lesions affect the face involving:

Remaining 10% can occur anywhere in body involving:

Traumatic neuroma[22][23][24][25] Positive for: Most common oral locations are:

Rarely involves:

Also known as:
Neurotized melanocytic nevus[26][27][28][29] Positive for:

Negative for:

Can occur anywhere in body, mostly involving following areas: _
Cutaneous myxoma (Superficial angiomyxoma)[30][31][32][33] Positive for:

Negative for:

Associated with Carney's complex/syndrome which includes following:

May be associated with NAME or LAMB syndrome

Nerve sheath myxoma[34][35][36][37][38][39] Positive for: _ Can occur anywhere in body:
Malignant peripheral nerve sheath tumor (MPNST)/malignant schwannoma[40][41][42][43][44][45]

Electron microscopy shows:

Positive for:

In case of glandular differentiation (malignant), positive for:

Negative for:

Associated with:

May be associated with:

Bulky deep-seated tumor usually arising from major nerves in:
Dermatofibrosarcoma protuberans (DFSP) Positive for:

Negative for:

Spindle cell lipoma Positive for:

Spindle cells are negative for:

  • Multiple well-circumscribed painless nodules involving several body parts
Ganglioneuroma[46][47] Genes involved in the pathogenesis of ganglioneuroma include:

Two histologic subtypes:

Positive for:

Negative for:

Ganglioneuromas may be associated with:

Located along distribution of sympathetic nervous system:

Symptoms of ganglioneuroma vary depending on the location of tumor, and include the following:

Patients with ganglioneuroma may also have paraneoplastic syndrome, which may manifest with:

Ganglioneuromas are included in the neuroblastic tumors group, which includes:

Myxoid liposarcoma[48][49][50][51][52][53][54][55][56][57]

Atypical lipomatous tumor/well differentiated liposarcoma and dedifferentiated liposarcoma are associated with:

Myxoid liposarcoma is associated with:

Pleomorphicliposarcoma is associated with:

Well-differentiated liposarcoma:

De-differentiated liposarcoma:

Atypical lipomatous tumor/well differentiated liposarcoma is positive for:


Positive for:

Negative for:

Inflammatory myofibroblastic tumor(IMT)[58][59][60][61][62][63][64][65][59][62][66]

Unknown underlying etiology, may be due to inflammatory reaction to:

Mutations such as:

Positive for:

Negative for:

Also known as:

Fibroepithelial polyp/Acrochordon[67][68][69][70][71][72][73][74][75][76][77][78][79][80][81][82][83][84][85][86] Associated with: Positive for:

Negative for:

Associated with:

Also known as:

History and Symptoms

Tumors are most commonly found on the torso and can also be found on the arms, legs, head, or neck.

Physical Examination

In dermatofibrosarcoma protuberans, the tumor most often starts as a small, firm patch of skin, usually 1 to 5 centimeters in diameter, that is usually purplish, reddish, or flesh-colored. The tumor typically grows slowly and can become a raised nodule. Occasionally, the tumor begins as a flat or depressed patch of skin (plaque).


Treatment is primarily surgical, with chemotherapy and radiation therapy sometimes being used.

There is clinical evidence that imatinib, which inhibits PDGFB, may be effective for tumors positive for the t(17;22) translocation.

CT images demonstrating a dermatofibrosarcoma protuberans in the right groin


Physical Examination




  2. Neurofibroma. Libre Pathology 2015. Accessed on November 17, 2015
  5. Rodriguez, Fausto J.; Folpe, Andrew L.; Giannini, Caterina; Perry, Arie (2012). "Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems". Acta Neuropathologica. 123 (3): 295–319. doi:10.1007/s00401-012-0954-z. ISSN 0001-6322.
  6. Choi, Kwangmin; Komurov, Kakajan; Fletcher, Jonathan S.; Jousma, Edwin; Cancelas, Jose A.; Wu, Jianqiang; Ratner, Nancy (2017). "An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system". Scientific Reports. 7 (1). doi:10.1038/srep43315. ISSN 2045-2322.
  7. Liao, Chung-Ping; Booker, Reid C.; Brosseau, Jean-Philippe; Chen, Zhiguo; Mo, Juan; Tchegnon, Edem; Wang, Yong; Clapp, D. Wade; Le, Lu Q. (2018). "Contributions of inflammation and tumor microenvironment to neurofibroma tumorigenesis". Journal of Clinical Investigation. 128 (7): 2848–2861. doi:10.1172/JCI99424. ISSN 0021-9738.
  8. 8.0 8.1 Staser, K.; Yang, F.-C.; Clapp, D. W. (2010). "Mast cells and the neurofibroma microenvironment". Blood. 116 (2): 157–164. doi:10.1182/blood-2009-09-242875. ISSN 0006-4971.
  9. Muir, David; Neubauer, Debbie; Lim, Ingrid T.; Yachnis, Anthony T.; Wallace, Margaret R. (2001). "Tumorigenic Properties of Neurofibromin-Deficient Neurofibroma Schwann Cells". The American Journal of Pathology. 158 (2): 501–513. doi:10.1016/S0002-9440(10)63992-2. ISSN 0002-9440.
  10. Wilkinson, Lana M.; Manson, David; Smith, Charles R. (2004). "Best Cases from the AFIP". RadioGraphics. 24 (suppl_1): S237–S242. doi:10.1148/rg.24si035170. ISSN 0271-5333.
  11. Bernthal, Nicholas; Jones, Kevin; Monument, Michael; Liu, Ting; Viskochil, David; Randall, R. (2013). "Lost in Translation: Ambiguity in Nerve Sheath Tumor Nomenclature and Its Resultant Treatment Effect". Cancers. 5 (4): 519–528. doi:10.3390/cancers5020519. ISSN 2072-6694.
  12. Mautner, V. F.; Friedrich, R. E.; von Deimling, A.; Hagel, C.; Korf, B.; Knöfel, M. T.; Wenzel, R.; Fünsterer, C. (2003). "Malignant peripheral nerve sheath tumours in neurofibromatosis type 1: MRI supports the diagnosis of malignant plexiform neurofibroma". Neuroradiology. 45 (9): 618–625. doi:10.1007/s00234-003-0964-6. ISSN 0028-3940.
  13. Shen, M H; Harper, P S; Upadhyaya, M (1996). "Molecular genetics of neurofibromatosis type 1 (NF1)". Journal of Medical Genetics. 33 (1): 2–17. doi:10.1136/jmg.33.1.2. ISSN 1468-6244.
  14. Rubin, Joshua B.; Gutmann, David H. (2005). "Neurofibromatosis type 1 — a model for nervous system tumour formation?". Nature Reviews Cancer. 5 (7): 557–564. doi:10.1038/nrc1653. ISSN 1474-175X.
  15. Gray, Mark H. (1990). "Immunohistochemical Demonstration of Factor XIIIa Expression in Neurofibromas". Archives of Dermatology. 126 (4): 472. doi:10.1001/archderm.1990.01670280056009. ISSN 0003-987X.
  16. Schwannoma. Dr Tim Luijkx and Dr Sara Wein et al.
  17. Vestibular Schwannoma. Wikipedia(2015) Accessed on October 2 2015
  18. Giordano J, Rogers LV (1989). "Peripherally administered serotonin 5-HT3 receptor antagonists reduce inflammatory pain in rats". European Journal of Pharmacology. 170 (1–2): 83–6. PMID 2612565. |access-date= requires |url= (help)
  19. Kolvenbach H, Lauven PM, Schneider B, Kunath U (1989). "Repetitive intercostal nerve block via catheter for postoperative pain relief after thoracotomy". The Thoracic and Cardiovascular Surgeon. 37 (5): 273–6. doi:10.1055/s-2007-1020331. PMID 2588243. Retrieved 2015-11-20.
  20. Opaleva-Stegantseva VA, Ivanov AG, Gavrilina IA, Khar'kov EI, Ratovskaia VI (1986). "[Incidence of sudden death cases in acute coronary insufficiency and acute myocardial infarction at the pre-hospital stage in Krasnoyarsk]". Kardiologiia (in Russian). 26 (5): 23–6. PMID 3735913. |access-date= requires |url= (help)
  21. Misago N, Inoue T, Narisawa Y (2007). "Unusual benign myxoid nerve sheath lesion: myxoid palisaded encapsulated neuroma (PEN) or nerve sheath myxoma with PEN/PEN-like features?". Am J Dermatopathol. 29 (2): 160–4. doi:10.1097/ PMID 17414438.
  22. Lee EJ, Calcaterra TC, Zuckerbraun L (1998). "Traumatic neuromas of the head and neck". Ear Nose Throat J. 77 (8): 670–4, 676. PMID 9745184.
  23. Hanna SA, Catapano J, Borschel GH (2016). "Painful pediatric traumatic neuroma: surgical management and clinical outcomes". Childs Nerv Syst. 32 (7): 1191–4. doi:10.1007/s00381-016-3109-z. PMID 27179535.
  24. Foltán R, Klíma K, Spacková J, Sedý J (2008). "Mechanism of traumatic neuroma development". Med Hypotheses. 71 (4): 572–6. doi:10.1016/j.mehy.2008.05.010. PMID 18599222.
  25. Yao C, Zhou X, Zhao B, Sun C, Poonit K, Yan H (2017). "Treatments of traumatic neuropathic pain: a systematic review". Oncotarget. 8 (34): 57670–57679. doi:10.18632/oncotarget.16917. PMC 5593675. PMID 28915703.
  26. Gray MH, Smoller BR, McNutt NS, Hsu A (1990). "Neurofibromas and neurotized melanocytic nevi are immunohistochemically distinct neoplasms". Am J Dermatopathol. 12 (3): 234–41. PMID 1693815.
  27. Chen Y, Klonowski PW, Lind AC, Lu D (2012). "Differentiating neurotized melanocytic nevi from neurofibromas using Melan-A (MART-1) immunohistochemical stain". Arch Pathol Lab Med. 136 (7): 810–5. doi:10.5858/arpa.2011-0335-OA. PMID 22742554.
  28. Singh N, Chandrashekar L, Kar R, Sylvia MT, Thappa DM (2015). "Neurotized congenital melanocytic nevus resembling a pigmented neurofibroma". Indian J Dermatol. 60 (1): 46–50. doi:10.4103/0019-5154.147789. PMC 4318062. PMID 25657396.
  29. Gray MH, Smoller BR, McNutt NS, Hsu A (1990). "Immunohistochemical demonstration of factor XIIIa expression in neurofibromas. A practical means of differentiating these tumors from neurotized melanocytic nevi and schwannomas". Arch Dermatol. 126 (4): 472–6. PMID 1690969.
  31. Alaiti, Samer; Nelson, Fern P.; Ryoo, Jei W. (2000). "Solitary cutaneous myxoma". Journal of the American Academy of Dermatology. 43 (2): 377–379. doi:10.1067/mjd.2000.101878. ISSN 0190-9622.
  32. Carney, J. Aidan (1986). "Cutaneous Myxomas". Archives of Dermatology. 122 (7): 790. doi:10.1001/archderm.1986.01660190068018. ISSN 0003-987X.
  33. Iida, Ken; Egi, Takeshi; Shigi, Masato; Sogabe, Yusuke; Ohashi, Hirotsugu (2019). "Cutaneous Myxoma of Multiple Lesions". Plastic and Reconstructive Surgery - Global Open. 7 (2): e2040. doi:10.1097/GOX.0000000000002040. ISSN 2169-7574.
  34. Fetsch JF, Laskin WB, Miettinen M (2005). "Nerve sheath myxoma: a clinicopathologic and immunohistochemical analysis of 57 morphologically distinctive, S-100 protein- and GFAP-positive, myxoid peripheral nerve sheath tumors with a predilection for the extremities and a high local recurrence rate". Am J Surg Pathol. 29 (12): 1615–24. PMID 16327434.
  35. Yadav SK, Singh S, Sarin N, Naeem R, Pruthi SK (2019). "Nerve Sheath Myxoma of Scalp: A Rare Site of Presentation". Int J Trichology. 11 (1): 34–37. doi:10.4103/ijt.ijt_45_18. PMC 6385516. PMID 30820132.
  36. Bhat A, Narasimha A, C V, Vk S (2015). "Nerve sheath myxoma: report of a rare case". J Clin Diagn Res. 9 (4): ED07–9. doi:10.7860/JCDR/2015/10911.5810. PMC 4437072. PMID 26023558.
  37. Avninder S, Ramesh V, Vermani S (2007). "Benign nerve sheath myxoma (myxoid neurothekeoma) in the leg". Dermatol Online J. 13 (2): 14. PMID 17498433.
  38. Kim BW, Won CH, Chang SE, Lee MW (2014). "A case of nerve sheath myxoma on finger". Indian J Dermatol. 59 (1): 99–101. doi:10.4103/0019-5154.123526. PMC 3884944. PMID 24470676.
  39. Pulitzer DR, Reed RJ (1985). "Nerve-sheath myxoma (perineurial myxoma)". Am J Dermatopathol. 7 (5): 409–21. PMID 4091218.
  40. Valeyrie-Allanore, L.; Ismaili, N.; Bastuji-Garin, S.; Zeller, J.; Wechsler, J.; Revuz, J.; Wolkenstein, P. (2005). "Symptoms associated with malignancy of peripheral nerve sheath tumours: a retrospective study of 69 patients with neurofibromatosis 1". British Journal of Dermatology. 153 (1): 79–82. doi:10.1111/j.1365-2133.2005.06558.x. ISSN 0007-0963.
  41. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A (2002). "Malignant peripheral nerve sheath tumours in neurofibromatosis 1". J Med Genet. 39 (5): 311–4. PMC 1735122. PMID 12011145.
  42. Panigrahi S, Mishra SS, Das S, Dhir MK (2013). "Primary malignant peripheral nerve sheath tumor at unusual location". J Neurosci Rural Pract. 4 (Suppl 1): S83–6. doi:10.4103/0976-3147.116480. PMC 3808069. PMID 24174807.
  43. Ferrari A, Bisogno G, Carli M (2007). "Management of childhood malignant peripheral nerve sheath tumor". Paediatr Drugs. 9 (4): 239–48. doi:10.2165/00148581-200709040-00005. PMID 17705563.
  44. Neville H, Corpron C, Blakely ML, Andrassy R (2003). "Pediatric neurofibrosarcoma". J Pediatr Surg. 38 (3): 343–6, discussion 343-6. doi:10.1053/jpsu.2003.50105. PMID 12632346.
  45. Zehou, Ouidad; Fabre, Elizabeth; Zelek, Laurent; Sbidian, Emilie; Ortonne, Nicolas; Banu, Eugeniu; Wolkenstein, Pierre; Valeyrie-Allanore, Laurence (2013). "Chemotherapy for the treatment of malignant peripheral nerve sheath tumors in neurofibromatosis 1: a 10-year institutional review". Orphanet Journal of Rare Diseases. 8 (1): 127. doi:10.1186/1750-1172-8-127. ISSN 1750-1172.
  46. Vasiliadis, K.; Papavasiliou, C.; Fachiridis, D.; Pervana, S.; Michaelides, M.; Kiranou, M.; Makridis, C. (2012). "Retroperitoneal extra-adrenal ganglioneuroma involving the infrahepatic inferior vena cava, celiac axis and superior mesenteric artery: A case report". International Journal of Surgery Case Reports. 3 (11): 541–543. doi:10.1016/j.ijscr.2012.07.008. ISSN 2210-2612.
  48. Khin Thway, Rashpal Flora, Chirag Shah, David Olmos & Cyril Fisher (2012). "Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors". The American journal of surgical pathology. 36 (3): 462–469. doi:10.1097/PAS.0b013e3182417330. PMID 22301498. Unknown parameter |month= ignored (help)
  49. J. Rosai, M. Akerman, P. Dal Cin, I. DeWever, C. D. Fletcher, N. Mandahl, F. Mertens, F. Mitelman, A. Rydholm, R. Sciot, G. Tallini, H. Van den Berghe, W. Van de Ven, R. Vanni & H. Willen (1996). "Combined morphologic and karyotypic study of 59 atypical lipomatous tumors. Evaluation of their relationship and differential diagnosis with other adipose tissue tumors (a report of the CHAMP Study Group)". The American journal of surgical pathology. 20 (10): 1182–1189. PMID 8827023. Unknown parameter |month= ignored (help)
  50. Dal Cin, Paola; Kools, Patrick; Sciot, Raf; De Wever, Ivo; Van Damme, Boudewijn; Van de Ven, Wim; Van Den Berghe, Herman (1993). "Cytogenetic and fluorescence in situ hybridization investigation of ring chromosomes characterizing a specific pathologic subgroup of adipose tissue tumors". Cancer Genetics and Cytogenetics. 68 (2): 85–90. doi:10.1016/0165-4608(93)90001-3. ISSN 0165-4608.
  51. Dei Tos, Angelo P.; Doglioni, Claudio; Piccinin, Sara; Sciot, Raf; Furlanetto, Alberto; Boiocchi, Mauro; Dal Cin, Paola; Maestro, Roberta; Fletcher, Christopher D. M.; Tallini, Giovanni (2000). "Coordinated expression and amplification of theMDM2,CDK4, andHMGI-C genes in atypical lipomatous tumours". The Journal of Pathology. 190 (5): 531–536. doi:10.1002/(SICI)1096-9896(200004)190:5<531::AID-PATH579>3.0.CO;2-W. ISSN 0022-3417.
  52. Dei Tos, A (2000). "Liposarcoma: New entities and evolving concepts". Annals of Diagnostic Pathology. 4 (4): 252–266. doi:10.1053/adpa.2000.8133. ISSN 1092-9134.
  53. M. D. Kraus, L. Guillou & C. D. Fletcher (1997). "Well-differentiated inflammatory liposarcoma: an uncommon and easily overlooked variant of a common sarcoma". The American journal of surgical pathology. 21 (5): 518–527. PMID 9158675. Unknown parameter |month= ignored (help)
  54. P. Argani, F. Facchetti, G. Inghirami & J. Rosai (1997). "Lymphocyte-rich well-differentiated liposarcoma: report of nine cases". The American journal of surgical pathology. 21 (8): 884–895. PMID 9255251. Unknown parameter |month= ignored (help)
  55. H. L. Evans (1979). "Liposarcoma: a study of 55 cases with a reassessment of its classification". The American journal of surgical pathology. 3 (6): 507–523. PMID 534388. Unknown parameter |month= ignored (help)
  56. A. P. Dei Tos, T. Mentzel, P. L. Newman & C. D. Fletcher (1994). "Spindle cell liposarcoma, a hitherto unrecognized variant of liposarcoma. Analysis of six cases". The American journal of surgical pathology. 18 (9): 913–921. PMID 8067512. Unknown parameter |month= ignored (help)
  57. D. C. Dahlin, K. K. Unni & T. Matsuno (1977). "Malignant (fibrous) histiocytoma of bone--fact or fancy?". Cancer. 39 (4): 1508–1516. PMID 192432. Unknown parameter |month= ignored (help)
  58. 58.0 58.1 Coffin CM, Watterson J, Priest JR, Dehner LP (1995). "Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases". Am J Surg Pathol. 19 (8): 859–72. PMID 7611533.
  59. 59.0 59.1 59.2 59.3 Wenig BM, Devaney K, Bisceglia M (1995). "Inflammatory myofibroblastic tumor of the larynx. A clinicopathologic study of eight cases simulating a malignant spindle cell neoplasm". Cancer. 76 (11): 2217–29. PMID 8635024.
  60. 60.0 60.1 Ramachandra S, Hollowood K, Bisceglia M, Fletcher CD (1995). "Inflammatory pseudotumour of soft tissues: a clinicopathological and immunohistochemical analysis of 18 cases". Histopathology. 27 (4): 313–23. PMID 8847061.
  61. 61.0 61.1 Häusler M, Schaade L, Ramaekers VT, Doenges M, Heimann G, Sellhaus B (2003). "Inflammatory pseudotumors of the central nervous system: report of 3 cases and a literature review". Hum Pathol. 34 (3): 253–62. doi:10.1053/hupa.2003.35. PMID 12673560.
  62. 62.0 62.1 62.2 62.3 Rabban JT, Zaloudek CJ, Shekitka KM, Tavassoli FA (2005). "Inflammatory myofibroblastic tumor of the uterus: a clinicopathologic study of 6 cases emphasizing distinction from aggressive mesenchymal tumors". Am J Surg Pathol. 29 (10): 1348–55. PMID 16160478.
  63. 63.0 63.1 Kovach SJ, Fischer AC, Katzman PJ, Salloum RM, Ettinghausen SE, Madeb R; et al. (2006). "Inflammatory myofibroblastic tumors". J Surg Oncol. 94 (5): 385–91. doi:10.1002/jso.20516. PMID 16967468.
  64. 64.0 64.1 Coffin CM, Dehner LP, Meis-Kindblom JM (1998). "Inflammatory myofibroblastic tumor, inflammatory fibrosarcoma, and related lesions: an historical review with differential diagnostic considerations". Semin Diagn Pathol. 15 (2): 102–10. PMID 9606802.
  65. 65.0 65.1 Berardi RS, Lee SS, Chen HP, Stines GJ (1983). "Inflammatory pseudotumors of the lung". Surg Gynecol Obstet. 156 (1): 89–96. PMID 6336632.
  66. 66.0 66.1 Coffin CM, Hornick JL, Fletcher CD (2007). "Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases". Am J Surg Pathol. 31 (4): 509–20. doi:10.1097/01.pas.0000213393.57322.c7. PMID 17414097.
  67. Cukic O, Jovanovic MB (2019). "Large Fibroepithelial Polyp of the Palatine Tonsil". Ear Nose Throat J: 145561319841203. doi:10.1177/0145561319841203. PMID 30997841.
  68. Vatansever M, Dinç E, Dursun Ö, Oktay ÖÖ, Arpaci R (2019). "Atypical presentation of fibroepithelial polyp: a report of two cases". Arq Bras Oftalmol. doi:10.5935/0004-2749.20190050. PMID 30916216.
  69. Rexhepi M, Trajkovska E, Besimi F, Rufati N (2018). "Giant Fibroepithelial Polyp of Vulva: A Case Report and Review of Literature". Pril (Makedon Akad Nauk Umet Odd Med Nauki). 39 (2–3): 127–130. doi:10.2478/prilozi-2018-0051. PMID 30864355.
  70. Jabbour J, Chappell JR, Busby M, McCubbery NW, Brown DF, Park SJK; et al. (2019). "Glottic Obstruction from Fibroepithelial Polyp". Am J Case Rep. 20: 219–223. doi:10.12659/AJCR.914907. PMC 6388646. PMID 30778021.
  71. Hong P, Cai Y, Li Z, Fan S, Yang K, Hao H; et al. (2019). "Modified Laparoscopic Partial Ureterectomy for Adult Ureteral Fibroepithelial Polyp: Technique and Initial Experience". Urol Int. 102 (1): 13–19. doi:10.1159/000494804. PMID 30448831.
  72. Uçar M, Baş E, Akkoç A, Topçuoğlu M (2018). "Fibroepithelial Polyp of the Ureter: A Rare Cause of Hydronephrosis". J Endourol Case Rep. 4 (1): 166–168. doi:10.1089/cren.2018.0031. PMC 6225073. PMID 30426076.
  73. Chaker K, Rhouma SB, Daly KM, Zehani A, Bibi M, Chehida MAB; et al. (2019). "Benign fibroepithelial polyp of the ureter: A case report". Urol Case Rep. 22: 52–53. doi:10.1016/j.eucr.2018.10.019. PMC 6226574. PMID 30425926.
  74. Hajji F, Moufid K, Ghoundale O, Touiti D (2019). "A rare case of successful endoscopic management of a fibroepithelial polyp with intussusception of the ureter and periodic prolapse into bladder". Ann R Coll Surg Engl. 101 (2): e66–e70. doi:10.1308/rcsann.2018.0198. PMC 6351868. PMID 30421620.
  75. Lee H, Sade I, Gilani S, Zhong M, Lombardo G (2018). "A Giant Fibroepithelial Polyp of the Small Bowel Associated with High-Grade Obstruction". Am Surg. 84 (7): e210–e211. PMID 30401014.
  76. Chaker K (2019). "Benign fibroepithelial polyp of the ureter: A case report". Urol Case Rep. 22: 15–16. doi:10.1016/j.eucr.2018.09.021. PMC 6180234. PMID 30319938.
  77. Lozano-Peña AK, Lamadrid-Zertuche AC, Ocampo-Candiani J (2019). "Giant fibroepithelial polyp of the vulva". Australas J Dermatol. 60 (1): 70–71. doi:10.1111/ajd.12886. PMID 30009441.
  78. Eckstein M, Agaimy A, Woenckhaus J, Winter A, Bittmann I, Janzen J; et al. (2019). "DICER1 mutation-positive giant botryoid fibroepithelial polyp of the urinary bladder mimicking embryonal rhabdomyosarcoma". Hum Pathol. 84: 1–7. doi:10.1016/j.humpath.2018.05.015. PMID 29883781.
  79. Akdere H, Çevik G (2018). "Rare Fibroepithelial Polyp Extending Along the Ureter: A Case Report". Balkan Med J. 35 (3): 275–277. doi:10.4274/balkanmedj.2017.1537. PMC 5981127. PMID 29843497.
  80. Ballard DH, Rove KO, Coplen DE, Chen TY, Hulett Bowling RL (2018). "Fibroepithelial polyp causing urethral obstruction: Diagnosis by cystourethrogram". Clin Imaging. 51: 164–167. doi:10.1016/j.clinimag.2018.05.009. PMC 6404776. PMID 29800931.
  81. Amin A, Amin Z, Al Farsi AR (2018). "Septic presentation of a giant fibroepithelial polyp of the vulva". BMJ Case Rep. 2018. doi:10.1136/bcr-2017-222789. PMID 29574427.
  82. Gupta R, Smita S, Sinha R, Sinha N, Sinha L (2018). "Giant fibroepithelial polyp of the thigh and retroperitoneal fibromatosis in a young woman: a rare case". Skeletal Radiol. 47 (9): 1299–1304. doi:10.1007/s00256-018-2904-x. PMID 29487969.
  83. Rajeesh Mohammed PK, Choudhury BK, Dalai RP, Rana V (2017). "Fibroepithelial Polyp with Sebaceous Hyperplasia: A Case Report". Indian J Med Paediatr Oncol. 38 (3): 404–406. doi:10.4103/ijmpo.ijmpo_124_17. PMC 5686997. PMID 29200704.
  84. Lee MH, Hwang JY, Lee JH, Kim DH, Song SH (2017). "Fibroepithelial polyp of the vulva accompanied by lymphangioma circumscriptum". Obstet Gynecol Sci. 60 (4): 401–404. doi:10.5468/ogs.2017.60.4.401. PMC 5547092. PMID 28791276.
  85. Ten Donkelaar CS, Houwert AC, Ten Kate FJW, Lock MTWT (2017). "Polypoid arteriovenous malformation of the ureter mimicking a fibroepithelial polyp, a case report". BMC Urol. 17 (1): 55. doi:10.1186/s12894-017-0237-z. PMC 5504856. PMID 28693464.
  86. Saito N, Yamasaki M, Daido W, Ishiyama S, Deguchi N, Taniwaki M (2017). "A bronchial fibroepithelial polyp with abnormal findings on auto-fluorescence imaging". Respirol Case Rep. 5 (5): e00244. doi:10.1002/rcr2.244. PMC 5465754. PMID 28603622.
  87. 87.0 87.1 87.2 87.3 87.4 87.5 87.6 87.7 87.8 87.9 "Dermatology Atlas".

External links